You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

3-antigen

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatitis B Trial in Hanoi (Sci-B-Vac-Lot B, Sci-B-Vac-Lot A, Engerix-B)

Completed
Has Results
  • Hepatitis B
  • Sci-B-Vac-Lot B
  • +2 more
  • Hanoi, Vietnam
    National Institute of Hygiene and Epidemiology (NIHE)
Jul 18, 2022

Psoriasis, Atopic Dermatitis Trial in Taipei (UVB treatment)

Recruiting
  • Psoriasis
  • Atopic Dermatitis
  • UVB treatment
  • Taipei, Taiwan
    National Taiwan University Hospital
Nov 24, 2022

dapted Strategy Including Magnetic Resonance Imaging and

Completed
  • Prostate Cancer
  • Prostate Adenocarcinoma
    • Ankara, Turkey
      Ankara University School of Medicine
    Sep 6, 2023

    Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung Trial (LB2102)

    Not yet recruiting
    • Small Cell Lung Cancer Extensive Stage
    • Large Cell Neuroendocrine Carcinoma of the Lung
    • LB2102
    • (no location specified)
    Jan 10, 2023

    Brain and Nervous System Trial in Palo Alto (B7-H3CART)

    Recruiting
    • Brain and Nervous System
    • Palo Alto, California
      Stanford Cancer Institute
    Jul 22, 2022

    COVID Infection in Pediatric Surgical Patient

    Recruiting
    • COVID-19
    • Rapid antigen test
    • Surrey, British Columbia, Canada
      Salem Anaesthesia Pain Clinic
    Jun 9, 2023

    Advanced Hepatocellular Carcinoma Trial (EU307 CAR-T Cell)

    Not yet recruiting
    • Advanced Hepatocellular Carcinoma
    • EU307 CAR-T Cell
    • (no location specified)
    Mar 13, 2023

    Liver Cell Carcinoma Trial in Houston (CATCH T cells, Cytoxan, Fludara)

    Recruiting
    • Liver Cell Carcinoma
    • +7 more
    • CATCH T cells
    • +2 more
    • Houston, Texas
      Houston Methodist Hospital
    Dec 19, 2022

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • São Paulo, Brazil
      Hospital Israelita Albert Einstein
    Jan 20, 2023

    Glioblastoma Multiforme Trial in Chapel Hill (CAR.B7-H3T cells infusion)

    Recruiting
    • Glioblastoma Multiforme
    • CAR.B7-H3T cells infusion
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center
    Oct 25, 2022

    Hepatocellular Carcinoma Trial in China (CAR-GPC3 T Cells)

    Completed
    • Hepatocellular Carcinoma
    • CAR-GPC3 T Cells
    • Guangzhou, Guangdong, China
    • +5 more
    Feb 8, 2022

    Liver Carcinoma, Hepatic Cell Carcinoma Trial in Wuhan (CAR-GPC3 T cells)

    Recruiting
    • Liver Carcinoma
    • Hepatic Cell Carcinoma
    • CAR-GPC3 T cells
    • Wuhan, Hubei, China
      Tao Zhang
    Nov 20, 2023

    Neuroblastoma Trial in Houston (iC9-GD2 T Cells - frozen, iC9-GD2 T Cells - fresh, Cytoxan)

    Active, not recruiting
    • Neuroblastoma
    • iC9-GD2 T Cells - frozen
    • +5 more
    • Houston, Texas
    • +1 more
    Jan 4, 2023

    Prostate Cancer, Prostate Adenocarcinoma, Prostatic Tumors Trial in Montreal (131I-PSMA-1095 Radioligand Therapy (RLT))

    Active, not recruiting
    • Prostate Cancer
    • +5 more
    • 131I-PSMA-1095 Radioligand Therapy (RLT)
    • Montreal, Quebec, Canada
      Stephan Probst
    Oct 24, 2022

    Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +4 more
    • CD19-targeted chimeric antigen receptor T-cell
    • Kaohsiung, Taiwan
    • +2 more
    Oct 25, 2022

    Chronic Kidney Disease (CKD) Trial in New Haven, New York, Philadelphia (REGN5459, REGN5458)

    Not yet recruiting
    • Chronic Kidney Disease (CKD)
    • New York, New York
      New York University Langone Health - Transplant Institute
    Jul 11, 2022

    Hepatocellular Carcinoma Trial in Houston (GLYCAR T cells, Cytoxan, Fludarabine)

    Active, not recruiting
    • Hepatocellular Carcinoma
    • GLYCAR T cells
    • +2 more
    • Houston, Texas
      Houston Methodist Hospital
    Feb 13, 2022

    Recurrent Glioblastoma, Refractory Glioblastoma Trial in Hangzhou, Huzhou, Ningbo (Temozolomide, B7-H3 CAR-T)

    Recruiting
    • Recurrent Glioblastoma
    • Refractory Glioblastoma
    • Hangzhou, Zhejiang, China
    • +2 more
    Dec 25, 2022

    CNS Tumors, Atypical Teratoid/Rhabdoid Tumor, Diffuse Midline Glioma, H3 K27M-Mutant Trial in Memphis (B7-H3-CAR T cells)

    Not yet recruiting
    • Central Nervous System Neoplasms
    • +6 more
    • B7-H3-CAR T cells
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    Apr 18, 2023

    Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma Trial in Memphis (Fludarabine, Cyclophosphamide, MESNA)

    Recruiting
    • Pediatric Solid Tumor
    • +15 more
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    Jun 30, 2022

    Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed

    Recruiting
    • Relapsed Non Hodgkin Lymphoma
    • +2 more
    • autologous CD19-directed chimeric antigen receptor (CAR) T-cells
    • Calgary, Alberta, Canada
    • +5 more
    Jul 18, 2022

    B7-H3-positive Relapsed/ Refractory Neuroblastoma Trial in Tianjin (T cell injection targeting FLT3 chimeric antigen receptor)

    Not yet recruiting
    • B7-H3-positive Relapsed/ Refractory Neuroblastoma
    • T cell injection targeting FLT3 chimeric antigen receptor
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute and Hospital
    Nov 1, 2022

    COVAG - Covid-19 Antigen Study - Diagnostic Efficacy of

    Completed
    • COVID-19
    • +2 more
    • 3 nasopharyngeal swab
    • Leinfelden-Echterdingen, Germany
    • +1 more
    Oct 12, 2021

    Advanced Glioma, Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy Trial in Suzhou (Targeted IL-13 Ra2 UCAR-T cell

    Recruiting
    • Advanced Glioma
    • Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy
    • Targeted IL-13 Rα2 UCAR-T cell injection
    • Targeted B7-H3 UCAR-T cell injection
    • Suzhou, Jiangsu, China
      The Second Affiliated Hospital of Soochow University
    Mar 2, 2023

    Diffuse Midline Glioma, H3 K27M-Mutant Trial (GD2 CAR T cells)

    Not yet recruiting
    • Diffuse Midline Glioma, H3 K27M-Mutant
    • GD2 CAR T cells
    • (no location specified)
    Sep 15, 2022